Insider Selling: OptiNose, Inc. (NASDAQ:OPTN) CEO Sells $171,198.75 in Stock

OptiNose, Inc. (NASDAQ:OPTNGet Rating) CEO Peter K. Miller sold 48,225 shares of the firm’s stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $3.55, for a total value of $171,198.75. Following the completion of the transaction, the chief executive officer now owns 892,677 shares in the company, valued at approximately $3,169,003.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

OptiNose Trading Down 2.4 %

NASDAQ:OPTN opened at $3.67 on Friday. OptiNose, Inc. has a 1-year low of $1.46 and a 1-year high of $4.30. The business’s 50-day moving average price is $3.66 and its two-hundred day moving average price is $2.96. The firm has a market capitalization of $305.63 million, a price-to-earnings ratio of -3.37 and a beta of -0.08.

OptiNose (NASDAQ:OPTNGet Rating) last released its earnings results on Thursday, August 11th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The business had revenue of $20.58 million during the quarter, compared to analysts’ expectations of $22.30 million. Sell-side analysts predict that OptiNose, Inc. will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On OptiNose

Hedge funds have recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC raised its position in shares of OptiNose by 0.7% during the second quarter. Rice Hall James & Associates LLC now owns 887,584 shares of the company’s stock worth $3,249,000 after purchasing an additional 5,919 shares during the period. Renaissance Technologies LLC raised its position in shares of OptiNose by 8.3% during the second quarter. Renaissance Technologies LLC now owns 284,700 shares of the company’s stock worth $1,042,000 after purchasing an additional 21,800 shares during the period. Bleichroeder LP raised its position in shares of OptiNose by 0.6% during the first quarter. Bleichroeder LP now owns 3,742,189 shares of the company’s stock worth $9,243,000 after purchasing an additional 21,998 shares during the period. BlackRock Inc. raised its position in shares of OptiNose by 3.0% during the first quarter. BlackRock Inc. now owns 772,391 shares of the company’s stock worth $1,907,000 after purchasing an additional 22,161 shares during the period. Finally, Prelude Capital Management LLC raised its position in shares of OptiNose by 20.0% during the second quarter. Prelude Capital Management LLC now owns 150,000 shares of the company’s stock worth $549,000 after purchasing an additional 25,000 shares during the period. Institutional investors and hedge funds own 44.67% of the company’s stock.

About OptiNose

(Get Rating)

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.

Featured Stories

Insider Buying and Selling by Quarter for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.